Peptides, Patents & the Law
Peptides sit at the intersection of biology, medicinal chemistry, patent law, drug regulation, pharmacy law, and commercial enforcement. A molecule can be patent-protected and still lack FDA approval. A patent can expire without making a product automatically lawful to sell. And a vial labeled “research use only” can still attract regulatory scrutiny if the surrounding marketing shows an intended human-drug use.
Latest legal development: Brazil orders seizure of United Labz products
Brazil's health regulator, Anvisa, ordered the seizure of all products sold under the United Labz brand and prohibited their manufacture, storage, distribution, sale, importation, advertising, and use in Brazil. Anvisa said the products were made by an unknown manufacturer and lacked required registration, notification, or sanitary authorization.
This is an official regulatory action, not merely a private-company allegation. It does not, by itself, establish that a particular product contained or did not contain the ingredient shown on its label, nor is it a criminal conviction. It establishes that Anvisa ordered the products removed from lawful commerce in Brazil on the regulatory grounds stated by the agency.
The action matters to retatrutide coverage because Anvisa has also separately warned that retatrutide remains investigational and is not approved for sale. Earlier in 2026, the agency ordered seizure of products labeled “Retatrutide 40 mg” and later reported finding retatrutide during enforcement operations involving irregular weight-loss products.
Primary sources: Anvisa — United Labz seizure order announcement; Anvisa — retatrutide approval-status warning; Anvisa — February 2026 seizure action.
Can a company “own” a peptide?
Not in the simplistic sense that often appears online. A company generally cannot claim ownership of a naturally occurring hormone merely because it discovered or isolated it. U.S. patent law has a product-of-nature doctrine, and patent eligibility is only the first hurdle: an invention must also satisfy requirements such as novelty, non-obviousness, and adequate disclosure.
But medicinal chemists can start with a natural peptide and engineer a molecule that does not occur in nature — for example by changing amino acids, introducing noncanonical residues, adding linkers or fatty-acid chains, or altering stability and receptor activity. A sufficiently novel and non-obvious engineered composition can be patentable.
The useful question is therefore not “Is this peptide natural?” It is “What exactly do the patent claims cover?”
What a peptide patent actually covers
A patent is principally a right to exclude others from practicing the claimed invention for the patent term. Depending on the claims, peptide intellectual property can cover a specific molecular sequence, a family of analogs, substitutions at defined positions, conjugates, formulations, manufacturing methods, or methods of use.
The description section of a patent may discuss hundreds of compounds. The legal boundary is driven primarily by the claims. Two patents that both mention GLP-1 can therefore have dramatically different scope.
Primary legal sources: 35 U.S.C. §101, §102, §103, and §271.
Case file: retatrutide
Retatrutide is an especially useful example because the internet often collapses two different ideas into one: “the body already has these hormones” and “therefore the drug cannot be patented.”
Human GIP, GLP-1, and glucagon are naturally occurring signaling molecules. Retatrutide is not simply one of those hormones placed in a vial. It is an engineered peptide analog designed to activate the GIP, GLP-1, and glucagon receptors, with deliberate structural modifications that affect its pharmacology and pharmacokinetics.
Lilly's U.S. Patent 11,542,313, titled Incretin Analogs and Uses Thereof, claims defined engineered incretin analogs and related subject matter. That is materially different from claiming ownership of GIP, GLP-1, glucagon, amino acids, or the receptors in the human body.
Patent source: U.S. Patent 11,542,313.
Lilly's 2026 retatrutide lawsuits
On August 12, 2026, Eli Lilly announced six federal lawsuits against U.S. businesses it accused of selling products represented as retatrutide. Those allegations are not court findings merely because a complaint was filed.
Importantly, the complaint reviewed by PeptideSciences101 in the Legendary Peptides matter pleads state unfair-competition and consumer-protection theories surrounding alleged sale of an unapproved drug; its enumerated causes of action do not include a patent-infringement count. That distinction is central to this section: patent enforcement and drug-law enforcement are different legal systems.
Sources: Lilly announcement, August 12, 2026 (company statement; allegations should not be treated as findings).
Patent law is not FDA law
A molecule can be patented and still be unapproved. A patent can expire while FDA restrictions remain. FDA approval can exist while patent rights still block a competitor from marketing a copy.
For retatrutide, FDA currently treats the molecule as investigational, not an FDA-approved drug. That regulatory status is independent of whether Lilly holds enforceable patent claims.
For a broader status comparison, see FDA-approved vs research-only peptides.
What “research use only” does — and does not — do
“Research use only” is not a magic phrase that overrides how a product is actually marketed. FDA evaluates evidence of intended use. Human-effect claims, weight-loss claims, administration or reconstitution context, and other surrounding conduct can matter even when a product page or vial also says “not for human consumption.”
That does not mean legitimate laboratory research reagents cannot be sold. It means the regulatory analysis is based on the full context, not solely on the disclaimer.
Related FDA reference: FDA — concerns with unapproved GLP-1 drugs used for weight loss.
503A / 503B compounding: a separate question again
Pharmacy compounding operates under separate provisions of federal law, principally sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Whether a bulk substance may be used in compounding depends on criteria that are distinct from patent ownership.
FDA has stated that retatrutide cannot currently be used in compounding under federal law because it is not a component of an FDA-approved drug and does not currently satisfy the applicable bulk substance pathways. That status can change only through the regulatory process — not because a seller calls a product a “research peptide.”
How to read a peptide patent without being a patent attorney
- Start with the independent claims. They define the broadest claimed inventions.
- Then read the dependent claims. These narrow the invention with additional structural or functional limitations.
- Find the sequence identifiers. A claim may point to a SEQ ID while the specification provides the actual sequence and modification map.
- Check the patent family. Continuations and related applications can produce multiple patents with different claim scope around the same development program.
- Check status and jurisdiction. A U.S. patent is not a worldwide monopoly, and an application is not the same as an issued, enforceable patent.
What PeptideSciences101 is watching
This section will be updated when a development materially changes the legal or regulatory picture: court rulings, injunctions, settlements, patent decisions, FDA warning letters or enforcement, 503A/503B changes, and significant actions by pharmaceutical companies or regulators in other major jurisdictions.
About this series: Peptides, Patents & the Law examines intellectual-property and regulatory issues for educational reference. Patent coverage can depend on claim construction, validity, jurisdiction, and facts not visible from a patent's title alone. Regulatory status can change. Nothing on this page constitutes legal advice or medical advice.